Søren Kragh Moestrup

Non-alcoholic steatohepatitis (NASH) is an epidemic inflammatory liver disease closely connected to obesity and the increasing consumption of high-caloric carbohydrates in soft drinks and food. So far, no effect medical therapy exists.

We have now developed a new antibody-based drug therapy targeting in liver macrophages and with profound effect in experimental NASH. The lecture will describe the drug development from the early molecular identification of the macrophage target (CD163) to animal studies and future plans.